PE20211860A1 - Proteinas de union multiespecificas que se unen a bcma, nkg2d y cd16 y metodos de uso - Google Patents

Proteinas de union multiespecificas que se unen a bcma, nkg2d y cd16 y metodos de uso

Info

Publication number
PE20211860A1
PE20211860A1 PE2021000169A PE2021000169A PE20211860A1 PE 20211860 A1 PE20211860 A1 PE 20211860A1 PE 2021000169 A PE2021000169 A PE 2021000169A PE 2021000169 A PE2021000169 A PE 2021000169A PE 20211860 A1 PE20211860 A1 PE 20211860A1
Authority
PE
Peru
Prior art keywords
binding site
bcma
seq
chain variable
domain
Prior art date
Application number
PE2021000169A
Other languages
English (en)
Inventor
Mitchell Bigelow
Gregory P Chang
Ann F Cheung
Asya Grinberg
William Haney
Nicolai Wagtmann
Bradley M Lunde
Bianka Prinz
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of PE20211860A1 publication Critical patent/PE20211860A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invencion se refiere a proteinas de union multiespecificas que comprenden un primer sitio de union a NKG2D, un segundo sitio de union al antigeno de maduracion de linfocitos B (BCMA) y un dominio Fc o parte de este para unirse a CD16 o un tercer sitio de union a CD16. Las proteinas de union de la invencion comprenden un primer sitio de union a NKG2D caracterizado por un dominio variable de cadena pesada que se selecciona de las SEQ ID NO: 94, 169, 171, 173, 175, 177 y 179; y un dominio variable de cadena ligera de SEQ ID NO: 98; un segundo sitio de union a BCMA caracterizado por un dominio variable de cadena pesada que se selecciona de las SEQ ID NO: 148, 114, entre otras; y un dominio variable de cadena ligera que se selecciona de las SEQ ID NO: 152, 119, entre otras; adicionalmente comprende un dominio Fc el cual es un dominio de Fc de IgG1 humana que comprende las sustituciones Q347R, D399V, F405T, K360E y/o K409W, entre otras. La invencion tambien se refiere a una formulacion, una celula y un metodo para tratar el cancer tal como: mieloma multiple, leucemia linfoblastica aguda, leucemia linfocitica cronica, linfomas de linfocitos B y leucemia mieloide aguda. Las proteinas de union multiespecificas proporcionadas en la presente exhiben alta potencia y lisis maxima de celulas cancerigenas objetivo en comparacion con anticuerpos monoclonales anti-BCMA.
PE2021000169A 2018-08-08 2019-08-08 Proteinas de union multiespecificas que se unen a bcma, nkg2d y cd16 y metodos de uso PE20211860A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862716207P 2018-08-08 2018-08-08
PCT/US2019/045632 WO2020033630A1 (en) 2018-08-08 2019-08-08 Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use

Publications (1)

Publication Number Publication Date
PE20211860A1 true PE20211860A1 (es) 2021-09-21

Family

ID=69413838

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000169A PE20211860A1 (es) 2018-08-08 2019-08-08 Proteinas de union multiespecificas que se unen a bcma, nkg2d y cd16 y metodos de uso

Country Status (19)

Country Link
US (2) US20210317223A1 (es)
EP (1) EP3833392A4 (es)
JP (1) JP7515459B2 (es)
KR (1) KR20210043602A (es)
CN (1) CN112823022A (es)
AR (1) AR114544A1 (es)
AU (1) AU2019318083A1 (es)
BR (1) BR112021002072A2 (es)
CA (1) CA3108427A1 (es)
CL (1) CL2021000316A1 (es)
CO (1) CO2021001410A2 (es)
EA (1) EA202190468A1 (es)
IL (1) IL280512A (es)
MA (1) MA53293A (es)
MX (1) MX2021001524A (es)
PE (1) PE20211860A1 (es)
SG (1) SG11202100883SA (es)
TW (1) TW202019479A (es)
WO (1) WO2020033630A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019218136A1 (en) 2018-02-08 2020-08-13 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
US20230364230A1 (en) * 2020-09-11 2023-11-16 Engmab Sàrl Combination therapy for cancer
CN117881702A (zh) * 2021-08-03 2024-04-12 山东先声生物制药有限公司 一种cd16抗体及其应用
WO2023107956A1 (en) * 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2274008T3 (da) 2008-03-27 2014-05-12 Zymogenetics Inc Sammensætninger og fremgangsmåder til hæmning af PDGFRBETA og VEGF-A
CA2761233A1 (en) 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
TW201109438A (en) 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2817015A1 (en) * 2010-11-09 2012-05-18 Altimab Therapeutics, Inc. Protein complexes for antigen binding and methods of use
US20140105915A1 (en) 2011-05-27 2014-04-17 Glaxo Group Limited Bcma (cd269/tnfrsf17) - binding proteins
US20140377269A1 (en) * 2012-12-19 2014-12-25 Adimab, Llc Multivalent antibody analogs, and methods of their preparation and use
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
SG11201704727WA (en) 2014-12-12 2017-07-28 Bluebird Bio Inc Bcma chimeric antigen receptors
JP6744313B2 (ja) 2015-01-02 2020-08-26 ダイアックス コーポレーション 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体
CN107530424A (zh) * 2015-02-20 2018-01-02 俄亥俄州国家创新基金会 针对nkg2d和肿瘤相关抗原的二价抗体
CN115160438A (zh) * 2015-04-06 2022-10-11 苏伯多曼有限责任公司 含有从头结合结构域的多肽及其用途
HUE048939T2 (hu) * 2015-08-03 2020-09-28 Engmab Sarl Human B sejt érési antigén elleni monoklonális antitestek (BCMA)
MA53750A (fr) 2015-08-17 2021-09-15 Janssen Pharmaceutica Nv Anticorps anti-bcma, molécules de liaison d'antigène bispécifiques qui se lient au bcma et cd3 et leurs utilisations
WO2017165464A1 (en) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
CA3044593A1 (en) * 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
BR112019016424A2 (pt) * 2017-02-10 2020-04-07 Dragonfly Therapeutics Inc proteínas de ligação a bcma, nkg2d e cd16

Also Published As

Publication number Publication date
WO2020033630A1 (en) 2020-02-13
EP3833392A1 (en) 2021-06-16
TW202019479A (zh) 2020-06-01
CO2021001410A2 (es) 2021-05-10
KR20210043602A (ko) 2021-04-21
JP2021533169A (ja) 2021-12-02
JP7515459B2 (ja) 2024-07-12
CN112823022A (zh) 2021-05-18
US20210317223A1 (en) 2021-10-14
MX2021001524A (es) 2021-04-19
SG11202100883SA (en) 2021-02-25
EA202190468A1 (ru) 2021-07-06
BR112021002072A2 (pt) 2021-06-01
CL2021000316A1 (es) 2021-07-30
AR114544A1 (es) 2020-09-16
EP3833392A4 (en) 2022-05-18
CA3108427A1 (en) 2020-02-13
AU2019318083A1 (en) 2021-02-25
US20220089760A1 (en) 2022-03-24
MA53293A (fr) 2021-11-17
IL280512A (en) 2021-03-25

Similar Documents

Publication Publication Date Title
PE20211860A1 (es) Proteinas de union multiespecificas que se unen a bcma, nkg2d y cd16 y metodos de uso
CL2020003028A1 (es) Anticuerpos anti-cd33, anticuerpos bispecíficos anti-cd33/anti-cd3 y sus usos.
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
PE20190120A1 (es) Moleculas de union a bcma y metodos de uso de las mismas
AR110017A1 (es) Anticuerpos de pd-1 y usos de estos
PE20190737A1 (es) Anticuerpos anti-cd27
PE20190356A1 (es) Receptores quimericos y metodos de uso de los mismos
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
PE20181921A1 (es) NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS
PE20241349A1 (es) Anticuerpos de union a cd3
PE20181451A1 (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
AR106570A1 (es) Anticuerpos anti-psma, moléculas de unión al antígeno biespecíficas que se unen a psma y cd3, y usos de estos
PE20180046A1 (es) Anticuerpos terapeuticos y sus usos
PE20240218A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5
PE20181044A1 (es) Anticuerpos anti-pd-1 y composiciones
AR106199A1 (es) Moléculas de unión a antígeno biespecíficas activadoras de células t
PE20210110A1 (es) Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso
CO2019012143A2 (es) Formulaciones estables de anticuerpos anti-ctla4 solos y en combinación con anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso
RU2018112649A (ru) Композиция для лечения рака, объединяющая анти-cd26 антитело и другое противораковое средство
EA202191785A1 (ru) Антитела к ctla4 и способы их применения
PE20180802A1 (es) Anticuerpos anti-cd154 y metodos de uso de estos
AR104906A1 (es) Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos
CO2022006909A2 (es) Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso
CO2023015859A2 (es) Anticuerpos para tratar alfa-sinucleinopatías